Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Human trials set for experimental HIV vaccine
Human trials set for experimental HIV vaccine
WEDNESDAY, June 6, 2018 -- An experimental HIV vaccine protected animals from dozens of strains of HIV.
Artificial bone marrow could take the fight to diseases of the blood
Artificial bone marrow could take the fight to diseases of the blood
A newly developed artificial bone marrow tissue could prove key to understanding the formation of human.
Study: Diuretic as effective as antibiotics to treat women's acne
Study: Diuretic as effective as antibiotics to treat women's acne
June 4 (UPI) -- Spironolactone, a diuretic drug, might be an effective alternative to antibiotics for the treatment of women's acne, according to a new study.
Phase II clinical study of elenbecestat demonstraytes safety and tolerability in MCI and mild to moderate Alzheimer’s disease at 18 months
Phase II clinical study of elenbecestat demonstraytes safety and tolerability in MCI and mild to moderate Alzheimer’s disease at 18 months
Eisai Co.
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R²) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R²) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
SUMMIT, N.
Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis
Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis
SOUTH SAN FRANCISCO, Calif.
Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
SUMMIT, N.
Roche stops olesoxime development
Roche stops olesoxime development
Today Roche announced they decision to stop the development of olesoxime, a neuroprotective drug that showed benefit in spinal muscular atrophy.
Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis
Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis
NEW YORK--(BUSINESS WIRE)--Pfizer Inc.
FDA approves first artificial iris
FDA approves first artificial iris
The U.
Madrigal's MGL-3196 shows sustained benefit in mid-stage NASH study; shares up 40% premarket
Madrigal's MGL-3196 shows sustained benefit in mid-stage NASH study; shares up 40% premarket
A Phase 2 clinical trial assessing Madrigal Pharmaceuticals' (NASDAQ.
AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
AB Science SA (NYSE Euronext – FR0010557264 – AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces its de...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand